Syinthetic delivery Systems for Brain targeted Therapies

My seminar will be focused on the development and implementation of delivery
technologies to improve the potential treatment of different brain diseases.
In the first part I will describe an innovative approach to use mRNA-lipid
nanoparticles (LNPs) to induce in situ brain reprogramming of astrocytes into
dopamine neurons for the potential therapeutic application in Parkinson’s disease.
In the second part I will show the generation of a new tool to improve brain targeting
using a single chain-camelid derived antibody (nanobody) against heparin-binding
EGF (HB-EGF). This newly generated nanobody is capable to cross the blood brain
barrier and can be used as innovative brain shuttle to deliver several therapeutic
agents to the brain.